{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:11:53Z","timestamp":1790435513752,"version":"4.1.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.1001\/jamadermatol.2019.1121","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T16:33:14Z","timestamp":1557505994000},"page":"1142","source":"Crossref","is-referenced-by-count":61,"title":["Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis"],"prefix":"10.1001","volume":"155","author":[{"given":"Erica D.","family":"Dommasch","sequence":"first","affiliation":[{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moa P.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Gagne","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi190030r1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","article-title":"Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.","volume":"9","author":"Stern","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"3","key":"doi190030r2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States.","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"doi190030r3","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"doi190030r4","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-a antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"issue":"9","key":"doi190030r5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"doi190030r6","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi190030r7","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","article-title":"Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.","volume":"74","author":"Doshi","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi190030r8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2018.06.053","article-title":"Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: a retrospective, comparative cohort study.","volume":"79","author":"Dommasch","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi190030r9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/jdv.2014.29.issue-1","article-title":"Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.","volume":"29","author":"Carretero","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi190030r10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi190030r11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi190030r12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jaad.2008.08.034","article-title":"Potential misclassification of patients with psoriasis in electronic databases.","volume":"59","author":"Icen","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi190030r13","doi-asserted-by":"publisher","first-page":"e020857","DOI":"10.1136\/bmjopen-2017-020857","article-title":"Validation of discharge diagnosis codes to identify serious infections among middle age and older adults.","volume":"8","author":"Wiese","year":"2018","journal-title":"BMJ Open"},{"issue":"7","key":"doi190030r14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"doi190030r15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.cpr.2013.02.002","article-title":"Researcher allegiance in psychotherapy outcome research: an overview of reviews.","volume":"33","author":"Munder","year":"2013","journal-title":"Clin Psychol Rev"},{"issue":"9596","key":"doi190030r17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"doi190030r18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM Registry.","volume":"137","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi190030r19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaad.2016.07.039","article-title":"Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries.","volume":"76","author":"Garcia-Doval","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi190030r20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (psolar).","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"8","key":"doi190030r21","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis.","volume":"136","author":"Yiu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi190030r22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jid.2017.10.005","article-title":"Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"138","author":"Yiu","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi190030r23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bjd.2019.180.issue-2","article-title":"Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"180","author":"Yiu","year":"2019","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi190030r24","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"doi190030r25","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"doi190030r26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/bjd.2008.159.issue-3","article-title":"Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.","volume":"159","author":"Schmitt","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi190030r27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2015.12.017","article-title":"Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).","volume":"74","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi190030r28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"doi190030r29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.2017.31.issue-3","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).","volume":"31","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi190030r30","first-page":"330","article-title":"Acitretin induces an increased adherence of S aureus to epithelial cells.","volume":"69","author":"Lianou","year":"1989","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"doi190030r31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bjd.1992.126.issue-4","article-title":"Staphylococcus aureus and intra-nasal mupirocin in patients receiving isotretinoin for acne.","volume":"126","author":"Williams","year":"1992","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi190030r32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/archderm.1986.01660190093024","article-title":"Isotretinoin and Staphylococcus aureus infection: a possible association.","volume":"122","author":"Graham","year":"1986","journal-title":"Arch Dermatol"},{"issue":"6","key":"doi190030r33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1080\/1120009X.1989.11738926","article-title":"Effects of synthetic retinoids on the growth of bacteria and their susceptibility to antibiotics.","volume":"1","author":"Flemetakis","year":"1989","journal-title":"J Chemother"},{"issue":"8","key":"doi190030r34","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","article-title":"Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom.","volume":"138","author":"Takeshita","year":"2018","journal-title":"J Invest Dermatol"},{"key":"doi190030r16","volume-title":"Accounting for sample overlap in meta-analysis","author":"Bom"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2733383\/jamadermatology_dommasch_2019_oi_190030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T11:01:04Z","timestamp":1570618864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2733383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.1121","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}